Related Experiment Videos
Progestogens in renal cell carcinoma. A retrospective study
European Urology
|January 1, 1979
Summary
This study examined renal cell carcinoma patients treated with progestogens. No survival difference was found between progesterone capronate and other treatments.
Area of Science:
- Oncology
- Endocrinology
Background:
- Renal cell carcinoma (RCC) is a significant cancer diagnosis.
- Progestogens have been explored for their therapeutic potential in various cancers.
Purpose of the Study:
- To evaluate the impact of progestogen administration, specifically progesterone capronate, on patient survival in renal cell carcinoma.
- To compare survival rates between patients receiving progesterone capronate and those on alternative therapeutic regimens.
Main Methods:
- A retrospective analysis of 88 renal cell carcinoma cases.
- Comparison of statistically homogeneous patient groups based on treatment received.
- Actuarial survival rate analysis.
Main Results:
- No statistically significant difference in actuarial survival rates was observed between patients treated with progesterone capronate and those receiving other therapeutic regimens.
- The study included 88 cases of renal cell carcinoma.
Conclusions:
- Progestogen administration, including progesterone capronate, did not demonstrate a statistically significant benefit in improving survival rates for renal cell carcinoma patients in this cohort.
- Further research may be warranted to explore other potential roles or specific subgroups where progestogens might be effective.